DOCSLIB.ORG

Ciprofibrate 100Mg Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ciprofibrate 100Mg Tablets Ciprofibrate contains lactose. - A blood disorder that makes you more likely to PACKAGE LEAFLET: INFORMATION FOR THE USER If you have been told by your doctor that you have infections (decrease in white cells) cannot tolerate some sugars, contact your - Some cases of pneumonia (pneumonitis) or doctor before taking ciprofibrate. increase of connective tissue in the lungs Ciprofibrate 100mg Tablets (pulmonary fibrosis) have been reported. 3. HOW TO TAKE CIPROFIBRATE The following side effects can happen at the Always take this medicine exactly as your doctor start of your treatment. You are less likely to • Read all of this leaflet carefully before you • you have kidney problems or a reduced has told you. Check with your doctor or get them as treatment continues: start using this medicine because it amount of a protein (albumin) in the blood, pharmacist if you are not sure. - Feeling sick (nausea) or being sick (vomiting) contains important information for you. such as when a particular disorder affecting Taking this medicine - Diarrhoea, indigestion or stomach pains Keep this leaflet. You may need to read it the kidneys occurs (nephrotic syndrome) - Take this medicine by mouth Reporting of side effects again. • you have liver problems - Do not give to children • If you have any further questions, ask your • you have an under-active thyroid gland If you get any side effects, talk to your doctor, - It is important while you are taking ciprofibrate pharmacist or nurse. This includes any possible doctor or pharmacist. • alcohol abuse to keep to any special diet you have been • This medicine has been prescribed for you • age greater than 70 years side effects not listed in this leaflet. You can also given report side effects directly via the Yellow Card only. Do not pass it on to others. It may harm • personal or family history of hereditary - If you feel the effect of your medicine is too them, even if their signs of illness are the muscular disorders Scheme at:www.mhra.gov.uk/yellowcard weak or too strong, do not change the dose By reporting side effects you can help provide same as yours. • previous history of muscular toxicity with yourself, but ask your doctor • If you get any side effects, talk to your doctor another fibrate. more information on the safety of this medicine. How much to take or pharmacist. This includes any possible side If you are not sure if any of the above applies to 5. HOW TO STORE CIPROFIBRATE effects not listed in this leaflet. you, talk to your doctor or pharmacist before - The usual dose for adults is 1 tablet every day taking ciprofibrate. - Do not take any more than 1 tablet each day • Keep this medicine out of the sight and reach What is in this leaflet Blood Tests - If you have kidney problems, only take 1 tablet of children. 1. What Ciprofibrate is and what it is used for every other day. • Do not use this medicine after the expiry date, 2. What you need to know before you take - Taking ciprofibrate may affect the results of some blood tests. During treatment your The break line is only there to help you break the which is stated on the blisters and carton. The Ciprofibrate expiry date refers to the last day of the month. 3. How to take Ciprofibrate doctor may do blood tests to check how your tablet if you have difficulty swallowing it whole. liver is working • Do not store above 25°C. Store in the original 4. Possible side effects If you take more Ciprofibrate than you should package to protect from moisture. 5. How to store Ciprofibrate - If you are going to have any other blood tests, If you take more of this medicine than you it is important to tell the person taking the test • Do not throw away any medicines via 6. Contents of the pack and other information should, talk to a doctor or go to a hospital wastewater or household waste. Ask your that you are taking ciprofibrate. straight away. Take the medicine pack with you. 1. WHAT CIPROFIBRATE IS AND pharmacist how to throw away medicines you Other medicines and Ciprofibrate WHAT IT IS USED FOR If you forget to take Ciprofibrate no longer use. These measures will help Tell your doctor or pharmacist if you - If you forget a dose, take it as soon protect the environment. The name of your medicine is Ciprofibrate are taking, have recently taken or as you remember it 100mg Tablets (called ciprofibrate throughout might take any other medicines. - However, if it is time for the next 6. CONTENTS OF THE PACK AND this leaflet). It contains a medicine called This is because ciprofibrate can affect dose, skip the missed dose OTHER INFORMATION ciprofibrate. This belongs to a group of the way some other medicines work. - Do not take a double dose to make What Ciprofibrate contains? medicines called ‘fibrates’. Also some medicines can affect the up for a forgotten dose. These medicines are used to lower the level of way ciprofibrate works. The active substance is ciprofibrate. Each tablet fats (lipids) in the blood. For example the fats Tell your doctor if you are taking any of If you stop taking Ciprofibrate contains 100 mg ciprofibrate. known as triglycerides. the following medicines: Keep taking your medicine until your doctor tells The other ingredients are lactose monohydrate, Ciprofibrate is used alongside a low fat diet and - Statins (such as simvastatin, atorvastatin, you to stop. Do not stop taking ciprofibrate just hydroxypropyl methyl cellulose, sodium lauril other non-medical treatments such as exercise pravastatin, fluvastatin and rosuvastatin) - because you feel better. If you stop, your illness sulphate, purified water, microcrystalline and weight loss, to lower levels of fats in the used to treat high blood fat levels may get worse. cellulose, maize starch and powdered vegetable blood. - Oral medicines used for thinning the blood, If you have any further questions on the use of stearing/hydrogenated vegetable oil. such as warfarin this medicine, ask your doctor or pharmacist. What Ciprofibrate Tablets look like and 2. WHAT YOU NEED TO KNOW BEFORE - Oral medicines used for diabetes, such as YOU TAKE CIPROFIBRATE 4. POSSIBLE SIDE EFFECTS contents of the pack metformin Ciprofibrate 100mg tablets are white to off white - Medicines containing oestrogens, such as Like all medicines, this medicine can cause side capsule shaped tablets plain on one side and Do not take Ciprofibrate: contraceptive medicines (such as “The Pill”) - if you are allergic to ciprofibrate or any of the effects, although not everybody gets them. with a break line on the other side. The break line or hormone replacement therapy (HRT) other ingredients of this medicine (listed in is only to facilitate breaking for ease of - Medicines for treating epilepsy, such as Stop taking your medicine and see a doctor or section 6) Signs of an allergic reaction swallowing and not to divide into equal doses. phenytoin go to a hospital straight away - you may need include: a rash, swallowing or breathing The tablets are supplied in blisters as a pack size - Other fibrates urgent medical treatment. problems, swelling of your lips, face, throat or of 28 tablets. Taking colestyramine or colestipol (other - Muscle problems, such as cramps, pain or tongue cholesterol-lowering drugs) at the same time can tenderness. This can lead to kidney failure Marketing Authorisation Holder - if you have previously taken ciprofibrate (or affect how well ciprofibrate works. These Focus Pharmaceuticals Limited, related substances) and your skin reacted Tell your doctor as soon as possible if you medicines should therefore not be taken at the Capital House, 85 King William Street, badly to sunlight have any of the following side effects: same time or within a short time of each other. London EC4N 7BL, UK - if you are pregnant, might become pregnant - An allergic reaction. The signs may include: a or think you may be pregnant (see Taking Ciprofibrate with alcohol rash (which may be itchy and lumpy), eczema, Manufacturer “Pregnancy and breast-feeding” section One of the side effects of this medicine is muscle itching and being more sensitive to the sun Mercury Pharmaceuticals Ltd., below) problems. Drinking a lot of alcohol may increase than usual Capital House, 85 King William Street, - if you are breast-feeding (see “Pregnancy and the chance of muscle problems. This means that - Feeling breathless London EC4N 7BL, UK breast-feeding” section below) you must limit the amount of alcohol you drink - Liver problems. This may cause the eyes or skin to go yellow (jaundice) - if you have severe liver or kidney problems while you are taking ciprofibrate. Ask your doctor This leaflet was last revised in April 2017 - if you are taking another fibrate (such as for more advice. - Severe pain in the upper right corner of your clofibrate, bezafibrate, fenofibrate or stomach, which could reach through to your Pregnancy and breast-feeding back. You may also have a fever and feel or be LF-102226-01 gemfibrozil) - to treat high blood fat levels. Do not take ciprofibrate if you are: Do not take this medicine if any of the above sick. This could be a sign of biliary colic or - Pregnant, might become pregnant, or think gallstones. applies to you. If you are not sure, talk to your you may be pregnant doctor or pharmacist before taking ciprofibrate. - Breast-feeding or planning to breast-feed. Other side effects are: Warnings and precautions If you are pregnant or breast-feeding, think you - Hair loss, balding Talk to your doctor or pharmacist before may be pregnant or are planning to have a baby, - Headache, balance problems taking Ciprofibrate if: ask your doctor or pharmacist for advice before - Feeling dizzy, drowsy or tired - you have unexpected muscle pains, taking this medicine.
Load more

Recommended publications
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Clofibrate Causes an Upregulation of PPAR- Target Genes but Does Not
    tapraid4/zh6-areg/zh6-areg/zh600707/zh65828d07a xppws S� 1 4/20/07 9: 48 MS: R-00603-2006 Ini: 07/rgh/dh A " #h!si$l %egul Integr &$ ' #h!si$l 2%&' R000 (R000) 200!$ 3. Originalarbeiten *irst publis#ed "arc# + 5) 200! doi' + 0$ + + 52,a-pregu$ 0060&$ 2006$ Clofibrate causes an upregulation of PPAR-� target genes but does not alter AQ: 1 expression of SREBP target genes in liver and adipose tissue of pigs Sebastian Luci, Beatrice Giemsa, Holger Kluge, and Klaus Eder Institut fu¨r Agrar- und Erna¨hrungswissenschaften, Martin-Luther-Universita¨t Halle-Wittenberg, Halle (Saale), Ger an! Submitted 25 August 2006 accepted in final form ! "arc# 200! AQ: 2 Luci S, Giemsa B, Kluge H, Eder K. Clofibrate causes an usuall0 increased 3#en baseline concentrations are lo3 1?62$ upregulation of PPAR-� target genes but does not alter expression of Effects of PPAR-� activation #ave been mostl0 studied in SREBP target genes in liver and adipose tissue of pigs$ A " #h!si$l rodents) 3#ic# ex#ibit a strong expression of PPAR-� in liver %egul Integr &$ ' #h!si$l 2%&' R000 (R000) 200!$ *irst publis#ed and s#o3 peroxisome proliferation in t#e liver in response to "arc# + 5) 200! doi' + 0$ + + 52,a-pregu$ 0060&$ 2006$ ./#is stud0 inves- PPAR-� activation 1&62$ Expression of PPAR-� and sensitivit0 tigated t#e effect of clofibrate treatment on expression of target genes of peroxisome proliferator-activated receptor 1PPAR2-� and various to peroxisomal induction b0 PPAR-� agonists) #o3ever) var0 genes of t#e lipid metabolism in liver and adipose tissue of pigs$ An greatl0
    [Show full text]
  • Joint Assessment Report Was Discussed by the Phvwp at Its Meeting in July 2007 and Finalised in September 2007
    ASSESSMENT REPORT on the benefit:risk of fibrates EXECUTIVE SUMMARY 1. BACKGROUND In the light of the established role of statins in the primary and secondary prevention of cardiovascular disease (CVD) and safety concerns arising from the use of fibrates, the CHMP Pharmacovigilance Working Party (PhVWP) agreed to undertake a benefit:risk assessment of this class of medicines. The objective was to establish the current place of fibrates in the treatment of cardiovascular and dyslipidaemic diseases, and in diabetes mellitus; also to provide recommendations regarding amendments of the Summary of Product Characteristics (SPC), as necessary. Fibrates exert their effects mainly by activating the peroxisome proliferator-activated receptor-alpha (PPAR-alpha). Unique in this class, bezafibrate is an agonist for all three PPAR isoforms alpha, gamma, and delta. Fibrates have been shown to reduce plasma triglycerides by 30% to 50% and raise the level of high density lipoprotein cholesterol (HDL- C) by 2% to 20%. Their effect on low density lipoprotein cholesterol (LDL-C) is variable, ranging from no effect to a small decrease of the order of 10%. Today there are four licensed fibrates: bezafibrate, fenofibrate, gemfibrozil and ciprofibrate. Their currently approved indications are quite broad and in many cases still use the old Fredrickson classification for dyslipidaemias. 2. METHODOLOGY In February 2006 a List of Questions was agreed by the PhVWP for the Marketing Authorisation Holders (MAHs) of medicinal products containing one of the four currently licensed fibrates (Annex 1). Other clofibrate-containing medicinal products (e.g. etofibrate, etofyllinclofibrate) were excluded from this class review, since these are available only in a few member states via national marketing authorizations.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Colesevelam Hydrochloride (Cholestagel) a New, Potent Bile Acid Sequestrant Associated with a Low Incidence of Gastrointestinal Side Effects
    ORIGINAL INVESTIGATION Colesevelam Hydrochloride (Cholestagel) A New, Potent Bile Acid Sequestrant Associated With a Low Incidence of Gastrointestinal Side Effects Michael H. Davidson, MD; Maureen A. Dillon; Bruce Gordon, MD; Peter Jones, MD; Julie Samuels, MD; Stuart Weiss, MD; Jonathon Isaacsohn, MD; Phillip Toth, MD; Steven K. Burke, MD Objectives: To compare colesevelam hydrochloride mg/dL) (19.1%) in the 3.75-g/d colesevelam treatment (Cholestagel), a nonabsorbed hydrogel with bile acid– group. Low-density lipoprotein cholesterol concentra- sequestering properties, with placebo for its lipid- tions at the end of treatment were significantly reduced lowering efficacy, its effects on laboratory and clinical from baseline levels in the 3.0- and 3.75-g/d colesevelam safety parameters, and the incidence of adverse events. treatment groups (P = .01 and P,.001, respectively). To- tal cholesterol levels demonstrated a similar response to Methods: Following diet and placebo lead-in periods, colesevelam treatment, with an 8.1% decrease from base- placebo or colesevelam was administered at 4 dosages (1.5, line in the 3.75-g/d treatment group (P<.001). High- 2.25, 3.0, or 3.75 g/d) for 6 weeks with morning and density lipoprotein cholesterol levels rose significantly evening meals to men and women with hypercholester- in the 3.0- and 3.75-g/d colesevelam treatment groups, olemia (low-density lipoprotein cholesterol level .4.14 by 11.2% (P = .006) and 8.1% (P = .02), respectively. mmol/L [.160 mg/dL]). Patients returned to the clinic Median triglyceride levels did not change from baseline, every 2 weeks throughout the treatment period for lipid nor were there any significant differences between parameter measurements and adverse event assess- treatment groups.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Etofibrate Item No. 21022 CAS Registry No.: 31637-97-5 Formal Name: ​3-pyridinecarboxylic acid, Cl 2-[2-(4-chlorophenoxy)-2-methyl- O 1-oxopropoxy]ethyl ester O Synonym: Nicotinic Acid O O N MF: C18H18ClNO5 O FW: 363.8 Purity: ≥98% UV/Vis.: λmax: 222, 263 nm Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Etofibrate is supplied as a crystalline solid. A stock solution may be made by dissolving the etofibrate in the solvent of choice. Etofibrate is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of etofibrate in ethanol and DMSO is approximately 80 mg/ml and approximately 50 mg/ml in DMF. Etofibrate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, etofibrate should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Etofibrate has a solubility of approximately 0.1 mg/ml in a 1:5 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Etofibrate is a combination of niacin and clofibrate (Item No. 10956) that acts as a hypolipidemic agent.1 In vivo, etofibrate decreases plasma cholesterol and triglyceride concentrations and increases bile cholesterol content in rats.1,2 It also decreases thromboxane formation, platelet aggregation, and plasma viscosity and inhibits neointima formation in a carotid artery balloon injury rat model.3 Formulations containing etofibrate have been used to treat hyperlipidemia.
    [Show full text]
  • Rosuvastatin
    Rosuvastatin Rosuvastatin Systematic (IUPAC) name (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan- 2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid Clinical data Trade names Crestor AHFS/Drugs.com monograph MedlinePlus a603033 Pregnancy AU: D category US: X (Contraindicated) Legal status AU: Prescription Only (S4) UK: Prescription-only (POM) US: ℞-only Routes of oral administration Pharmacokinetic data Bioavailability 20%[1] Protein binding 88%[1] Metabolism Liver (CYP2C9(major) andCYP2C19-mediated; only minimally (~10%) metabolised)[1] Biological half-life 19 hours[1] Excretion Faeces (90%)[1] Identifiers CAS Registry 287714-41-4 Number ATC code C10AA07 PubChem CID: 446157 IUPHAR/BPS 2954 DrugBank DB01098 UNII 413KH5ZJ73 KEGG D01915 ChEBI CHEBI:38545 ChEMBL CHEMBL1496 PDB ligand ID FBI (PDBe, RCSB PDB) Chemical data Formula C22H28FN3O6S Molecular mass 481.539 SMILES[show] InChI[show] (what is this?) (verify) Rosuvastatin (marketed by AstraZenecaas Crestor) 10 mg tablets Rosuvastatin, marketed as Crestor, is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It was developed by Shionogi. Crestor is the fourth- highest selling drug in the United States, accounting for approx. $5.2 billion in sales in 2013.[2] Contents [hide] 1Medical uses 2Side effects and contraindications 3Drug interactions 4Structure 5Mechanism of action 6Pharmacokinetics 7Indications and regulation
    [Show full text]
  • Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: the Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
    Diabetes Volume 65, July 2016 1767 Changting Xiao,1 Satya Dash,1 Cecilia Morgantini,1 Robert A. Hegele,2 and Gary F. Lewis1 Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol Diabetes 2016;65:1767–1778 | DOI: 10.2337/db16-0046 Notwithstanding the effectiveness of lowering LDL cho- has been the primary goal of dyslipidemia management, lesterol, residual CVD risk remains in high-risk popula- with statins as the treatment of choice for CVD prevention. tions, including patients with diabetes, likely contributed Large-scale, randomized, clinical trials of LDL-lowering PERSPECTIVES IN DIABETES to by non-LDL lipid abnormalities. In this Perspectives therapies have demonstrated significant reduction in CVD in Diabetes article, we emphasize that changing demo- events over a wide range of baseline LDL-C levels (2,3). graphics and lifestyles over the past few decades have However, even with LDL-C levels lowered substantially or “ resulted in an epidemic of the atherogenic dyslipidemia at treatment goals with statin therapy, CVD risks are not ” complex, the main features of which include hypertrigly- eliminated and there remains significant “residual risk.” In- ceridemia, low HDL cholesterol levels, qualitative changes tensifying statin therapy may provide additional benefits in LDL particles, accumulation of remnant lipoproteins, (4,5); this approach, however, has limited potential, owing and postprandial hyperlipidemia. We brieflyreviewthe to tolerability, side effects, and finite efficacy. Further LDL-C underlying pathophysiology of this form of dyslipidemia, lowering may also be achieved with the use of nonstatin in particular its association with insulin resistance, obe- sity, and type 2 diabetes, and the marked atherogenicity agents, such as cholesterol absorption inhibitors and PCSK9 of this condition.
    [Show full text]
  • PI Changes for Fibrates
    Changes to Product Information as approved by the CHMP on 21 October 2010, pending endorsement by the European Commission 1 BEZAFIBRATE ANNEX I -SUMMARY OF PRODUCT CHARACTERISTICS 4.1 Therapeutic indications (to replace current text) [Product name] is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following: - Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol. - Mixed hyperlipidaemia when a statin is contraindicated or not tolerated. 5.1 Pharmacodynamic properties (Additional text) There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease ANNEX III -LABELLING AND PACKAGE LEAFLET What [Product name] is and what it is used for [Product name] belongs to a group of medicines, commonly known as fibrates. These medicines are used to lower the level of fats (lipids) in the blood. For example the fats known as triglycerides. [Product name] is used, alongside a low fat diet and other non-medical treatments such as exercise and weight loss, to lower levels of fats in the blood. 2 CIPROFIBRATE ANNEX I -SUMMARY OF PRODUCT CHARACTERISTICS 4.1 Therapeutic indications (to replace current text) [Product name] is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following: - Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol. - Mixed hyperlipidaemia when a statin is contraindicated or not tolerated. 5.1 Pharmacodynamic properties (Additional text) There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease ANNEX III -LABELLING AND PACKAGE LEAFLET What [Product name] is and what it is used for [Product name] belongs to a group of medicines, commonly known as fibrates.
    [Show full text]
  • NCEP Drug Treatment
    NCEP Drug Treatment The information contained in this document is taken directly from the National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III) that is published by the National Institutes of Health – National Heart, Lung and Blood Institute. Major Classes of Drugs Available Affecting Lipoprotein Metabolism HMG CoA reductase inhibitors—lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin Bile acid sequestrants—cholestyramine, colestipol, colesevelam Nicotinic acid—crystalline, timed-release preparations, Niaspan® Fibric acid derivatives (fibrates)—gemfibrozil, fenofibrate, clofibrate Estrogen replacement Omega-3 fatty acids Major Uses and Lipid/ Lipoprotien Effects of Each Drug Class Drug Class Major Use Lipid/ Lipoprotein Effects LDL ↓ 18-55% HMG CoA reductase To lower LDL cholesterol HDL ↑ 5-15% inhibitors (statins) TG ↓ 7-30% LDL ↓ 15-30% Bile acid sequestrants To lower LDL cholesterol HDL ↑ 3-5% TG No effect or increase LDL ↓ 5-25% Useful in most lipid and Nicotinic acid HDL ↑ 15-35% lipoprotein abnormalities TG ↓ 20-50% LDL ↓ 5-20% (in nonhypertriglyceridemic persons); Hypertriglyceridemia; may be increased in hypertriglyceridemic persons Fibric acids Atherogenic dyslipidemia HDL ↑ 10-35% (more in severe hypertriglyceridemia) TG ↓ 20-50% NCEP Drug Treatment The information contained in this document is taken directly from the National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III) that is published by the National Institutes of Health – National Heart, Lung and
    [Show full text]
  • Fenofibrate, Bezafibrate, Ciprofibrate and Gemfibrozil Procedure Number
    28 February 2011 EMA/CHMP/580013/2012 Assessment report for fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil containing medicinal products pursuant to Article 31 of Directive 2001/83/EC, as amended INN: fenofibrate, bezafibrate, ciprofibrate and gemfibrozil Procedure number: EMEA/H/A-1238 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical aspects .................................................................................................... 4 2.2.1. PhVWP recommendation ..................................................................................... 4 2.2.2. CHMP review ..................................................................................................... 7 2.2.3. Discussion .....................................................................................................
    [Show full text]
  • Lipid Lowering Drugs Prescription and the Risk of Peripheral Neuropathy
    1047 J Epidemiol Community Health: first published as 10.1136/jech.2003.013409 on 16 November 2004. Downloaded from RESEARCH REPORT Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases Giovanni Corrao, Antonella Zambon, Lorenza Bertu`, Edoardo Botteri, Olivia Leoni, Paolo Contiero ............................................................................................................................... J Epidemiol Community Health 2004;58:1047–1051. doi: 10.1136/jech.2003.013409 Study objective: Although lipid lowering drugs are effective in preventing morbidity and mortality from cardiovascular events, the extent of their adverse effects is not clear. This study explored the association between prescription of lipid lowering drugs and the risk of peripheral neuropathy. Design: A population based case-control study was carried out by linkage of several automated databases. Setting: Resident population of a northern Italian Province aged 40 years or more. Participants: Cases were patients discharged for peripheral neuropathy in 1998–1999. For each case up See end of article for authors’ affiliations to 20 controls were randomly selected among those eligible. Altogether 2040 case patients and 36 041 ....................... controls were included in the study. Exposure ascertainment: Prescription drug database was used to assess exposure to lipid lowering drugs Correspondence to: Professor G Corrao, at any time in the one year period preceding the index date.
    [Show full text]